Exact Sciences — Nov 5, 2024 release

2024 outlook The Company has updated its full-year 2024 revenue and adjusted EBITDA guidance: Prior guidance November 5 update Total revenue $2.810 - $2.850 billion $2.730 - $2.750 billion Screening $2.155 - $2.175 billion $2.080 - $2.095 billion Precision Oncology $655 - $675 million $650 - $655 million Adjusted EBITDA $335 - $355 million $310 - $320 million Third-quarter 2024 conference call & webcast Company management will host a conference call and webcast on Tuesday, November 5, 2024, at 5 p.m. ET to discuss third-quarter 2024 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international callers is 4437608. A replay of the webcast will be available at exactsciences.com. The webcast, conference call, and replay are open to all interested parties. Non-GAAP disclosure In addition to the Company’s financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents core revenue, non-GAAP gross margin, non-GAAP gross profit, adjusted EBITDA, adjusted EBITDA margin, adjusted cost of sales (exclusive of amortization of acquired intangible assets), adjusted research and development expenses, adjusted sales and marketing expenses, adjusted general and administrative expenses, adjusted amortization of acquired intangible assets, adjusted impairment of long-liv